Boone Capital Management LLC Buys New Position in BioMarin Pharmaceutical Inc. $BMRN

Key Points

• Boone Capital Management acquired 583,219 BioMarin shares worth approximately $33.4 million, making BMRN about 7.8% of its portfolio and its sixth-largest holding. Institutional investors collectively own 98.71% of the company.
• BioMarin exceeded quarterly expectations, reporting $1.20 in EPS versus the $0.95 consensus and revenue of $989.71 million, up 20% year over year. The company issued fiscal 2026 EPS guidance of $4.90–$5.10.
• Analysts maintain a favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $88.79 versus the stock’s recent price of $65.61.

Boone Capital Management LLC purchased a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 583,219 shares of the biotechnology company's stock, valued at approximately $33,372,000. BioMarin Pharmaceutical makes up approximately 7.8% of Boone Capital Management LLC's portfolio, making the stock its 6th largest position. Boone Capital Management LLC owned approximately 0.30% of BioMarin Pharmaceutical at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Activest Wealth Management acquired a new stake in BioMarin Pharmaceutical in the fourth quarter valued at approximately $26,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of BioMarin Pharmaceutical during the second quarter worth $39,000. CIBC Private Wealth Group LLC lifted its position in shares of BioMarin Pharmaceutical by 38.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 179 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of BioMarin Pharmaceutical in the third quarter valued at $40,000. Finally, Parallel Advisors LLC boosted its stake in shares of BioMarin Pharmaceutical by 62.2% in the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company's stock valued at $42,000 after purchasing an additional 295 shares during the period. Hedge funds and other institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical Stock Down 0.8%

BMRN stock opened at $65.61 on Thursday. BioMarin Pharmaceutical Inc. has a twelve month low of $49.26 and a twelve month high of $70.98. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $12.70 billion, a P/E ratio of 177.32, a PEG ratio of 0.47 and a beta of 0.24. The firm has a 50 day simple moving average of $61.29 and a 200-day simple moving average of $58.05.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The firm had revenue of $989.71 million for the quarter, compared to analysts' expectations of $932.03 million. During the same period in the prior year, the company posted $1.44 earnings per share. The firm's quarterly revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, equities research analysts predict that BioMarin Pharmaceutical Inc. will post 4.1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. The Goldman Sachs Group started coverage on shares of BioMarin Pharmaceutical in a research note on Monday, May 11th. They set a "neutral" rating and a $69.00 price target on the stock. UBS Group set a $88.00 price objective on shares of BioMarin Pharmaceutical in a research report on Wednesday. Bank of America lowered their target price on BioMarin Pharmaceutical from $85.00 to $80.00 and set a "buy" rating for the company in a research note on Tuesday, May 19th. Wall Street Zen raised BioMarin Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Finally, Oppenheimer lifted their target price on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the stock an "outperform" rating in a research report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $88.79.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source